Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: results from a large cohort study

Lin, Chia Hsin; Chou, Wen Chi; Wu, Yao-Yu; Lin, Chien Yu; Chang, Kai Ping; Liao, Chun Ta; Ho, Tsung Ying; Yeh, Chiu Mei; Liu, Chia Jen; Hung, Sheng-Ping; Lee, Ching Hsin; Chen, Po Jui; Chou, Yung Chih; Fan, Kang‐Hsing; Huang, Bing; Chang, Joseph Tung-Chieh; Wang, Chun Chieh; Tsang, Ngan Ming

doi:10.1016/j.radonc.2020.09.012

Cited by 15 publications

(22 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the tumor CBX8 gene and protein level demonstrated a rather opposite pattern in its prognostic significance. Although tumor CBX8 gene level was not associated with DFS and OS of CRC patients in this study, our findings demonstrated that higher CBX8 level in tumor was associated with higher post-operative LMR and lower delta LMR, which have been reported as factors of better prognosis for CRC patients [ 30 , 31 ]. In addition, our data revealed that higher tumor CBX8 showed a trend towards lower tumor invasion.…”

Section: Discussioncontrasting

confidence: 55%

“…In addition, a higher tumor CBX8 gene level was correlated with lower delta-LMR (R = −0.433, p = 0.0007, Figure 3 E) and higher delta-eosinophil (R = 0.302, p = 0.0201, Figure 3 F). Though the prognostic value of these parameters has not been reported in CRC, low delta-LMR and high delta-eosinophil were associated with better OS or DFS in renal cell carcinoma and head and neck cancer patients [ 30 , 31 ], respectively. These correlations suggested that tumor CBX8 gene level is associated with better prognosis in CRC patients.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients

Ng¹,

Li²,

Man³

et al. 2022

Cells

View full text Add to dashboard Cite

Background: Several studies have demonstrated that the molecular profile of normal tissue adjacent to the tumor (NAT) is prognostic for recurrence in patients with different cancers. This study investigated the clinical significance of CBX8 gene expression, a cancer stemness-related gene, in tumor and NAT tissue of colorectal cancer (CRC) patients. Methods: The gene level of CBX8 in paired CRC and NAT specimens from 95 patients was determined by quantitative PCR. CBX8 protein level in CRC and NAT specimens from 66 patients was determined by immunohistochemistry. CBX8 gene and protein levels were correlated with the patients’ clinicopathological parameters and circulatory immune cell profiles. The association between CBX8 and pluripotency-associated genes was analyzed using the TCGA database. Results: NAT CBX8 gene level positively correlated with TNM stage, tumor invasion, lymph node metastasis and distant metastasis, indicating its association with tumor progression and metastasis. There was no correlation between NAT CBX8 protein level and clinicopathological parameters. Moreover, a high level of CBX8 gene and protein in NAT both correlated with poor DFS and OS. There was an inverse correlation between CBX8 gene level and post-operative platelet counts and platelet to lymphocyte level, suggesting its association with systematic inflammation. Finally, TCGA analysis showed that CBX8 level was correlated with a couple of pluripotency-associated genes, supporting its association with cancer stemness. Conclusions: High NAT CBX8 is a poor prognostic factor for tumor progression and survival in CRC patients.

show abstract

Section: Discussioncontrasting

confidence: 55%

Section: Resultsmentioning

confidence: 99%

High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients

Ng¹,

Li²,

Man³

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…This finding supports current available literature. In a large study by Lin et al, longitudinal analysis of inflammatory markers throughout radiotherapy treatment in 1,431 patients with HNC showed a significant association between delta LMR and overall survival (OS) and freedom from metastasis (FFM), with improved survival amongst patients with lower delta LMR [5]. Unlike the study by Lin and colleagues, in which only radiotherapy treatment was evaluated, our study evaluated delta prognostic factors with several different treatment modalities, including radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Treatment indication is based on diagnostic workup, which ultimately depends on several factors that are widely accepted as indicators of prognosis in patients with HNSCC. The classic prognostic factors include tumor differentiation, site, size, nodal involvement, metastasis, tumor grading, in addition to age and various comorbidities [3][4][5][6]. Smoking and alcohol usage status have also classically been useful in indicating tumor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Investigation of the Relationship between Delta Inflammatory Markers and Prognosis in Head and Neck Squamous Cell Carcinoma

Khaymovich

Wong

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Inflammatory markers, such as Lymphocyte-to-Monocyte Ratio (LMR), Neutrophil-to-Lymphocyte Ratio (NLR), and Platelet-to-Lymphocyte Ratio (PLR), have been shown to hold significant prognostic value in the context of head and neck cancer (HNC). Recently, delta inflammatory markers, the difference between pre and post- treatment inflammatory marker ratios, have been suggested as potentially significant values in predicting cancer prognosis. Our objective was to evaluate the prognostic utility of delta LMR, NLR, and PLR in head and neck squamous cell carcinoma (HNSCC). Methods: Retrospective cohort study in a tertiary academic hospital setting. Patients diagnosed with HNSCC in the oral cavity, larynx, and oropharynx treated with curative intent treatment were included. The variables collected were age, sex, BMI, alcohol/tobacco exposure, performance scores, ACE-27, tumor characteristics, adjuvant treatment, ECOG score, and lab values. Overall Survival (OS) and Event-Free Survival (EFS) were chosen as endpoints. OS was defined as time from date of treatment to date of last follow-up or death from any cause, and EFS was defined as the start of treatment to any progression, recurrence, or death from any cause. Univariate and multivariate analyses were performed on the primary endpoints. Results: A total of 89 patients were included from 2010 to 2017. In multivariate analysis, EFS was found to be significantly associated with an N stage of 3 (p=0.0005) and delta LMR > -1.48 (p=0.0241). No significant relationships were uncovered with OS in multivariate analysis. Conclusion: A higher delta LMR value (>-1.48) was associated with poorer EFS, but was not associated with OS.

show abstract

“…As critical parameters of inflammation, amounts of monocytes or lymphocyte-monocytes ratio (LMR), and content of circulating monocytes subpopulations compositions can have diagnostic and prognostic significance (summarized in Table 1) (31,32,(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(63)(64)(65)(66)(67)(68). Unambiguously attractive is the fact that monocytes circulate in blood that makes them minimally invasive biomarkers and accessible cell targets for therapy.…”

Section: Introductionmentioning

confidence: 99%

Monocyte programming by cancer therapy

et al. 2022

View full text Add to dashboard Cite

Monocytes in peripheral blood circulation are the precursor of essential cells that control tumor progression, that include tumor-associated macrophages (TAMs), dendritic cells (DCs) and myeloid-derive suppressor cells (MDSC). Monocytes-derived cells orchestrate immune reactions in tumor microenvironment that control disease outcome and efficiency of cancer therapy. Four major types of anti-cancer therapy, surgery, radiotherapy, chemotherapy, and most recent immunotherapy, affect tumor-associated macrophage (TAM) polarization and functions. TAMs can also decrease the efficiency of therapy in a tumor-specific way. Monocytes is a major source of TAMs, and are recruited to tumor mass from the blood circulation. However, the mechanisms of monocyte programming in circulation by different therapeutic onsets are only emerging. In our review, we present the state-of-the art about the effects of anti-cancer therapy on monocyte progenitors and their dedifferentiation, on the content of monocyte subpopulations and their transcriptional programs in the circulation, on their recruitment into tumor mass and their potential to give origin for TAMs in tumor-specific microenvironment. We have also summarized very limited available knowledge about genetics that can affect monocyte interaction with cancer therapy, and highlighted the perspectives for the therapeutic targeting of circulating monocytes in cancer patients. We summarized the knowledge about the mediators that affect monocytes fate in all four types of therapies, and we highlighted the perspectives for targeting monocytes to develop combined and minimally invasive anti-cancer therapeutic approaches.

show abstract

Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: results from a large cohort study

Cited by 15 publications

References 67 publications

High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients

High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients

Investigation of the Relationship between Delta Inflammatory Markers and Prognosis in Head and Neck Squamous Cell Carcinoma

Monocyte programming by cancer therapy

Contact Info

Product

Resources

About